Copyright
©The Author(s) 2022.
World J Gastrointest Surg. Jul 27, 2022; 14(7): 670-684
Published online Jul 27, 2022. doi: 10.4240/wjgs.v14.i7.670
Published online Jul 27, 2022. doi: 10.4240/wjgs.v14.i7.670
Figure 3 Overall survival and recurrence-free survival rates of patients with renal dysfunction after propensity score matching.
A: The median survival time was 76.5 mo in patients with renal dysfunction (RD) and 73.0 mo in patients without RD, so overall survival was similar between the RD and non-RD groups (P = 0.343) after propensity score matching (PSM); B: Recurrence-free survival also did not differ significantly between the RD and non-RD groups after PSM (P = 0.314) after PSM. RD: Renal dysfunction.
- Citation: Sakamoto Y, Shimada S, Kamiyama T, Sugiyama K, Asahi Y, Nagatsu A, Orimo T, Kakisaka T, Kamachi H, Ito YM, Taketomi A. Impact of comorbid renal dysfunction in patients with hepatocellular carcinoma on long-term outcomes after curative resection. World J Gastrointest Surg 2022; 14(7): 670-684
- URL: https://www.wjgnet.com/1948-9366/full/v14/i7/670.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v14.i7.670